Trastuzumab in combination with chemotherapy for HER2-positive metastatic gastric cancer patients underwent conversion therapy
文献类型：期刊论文
| 作者 | Zhang, Yanqiang3; Xu, Xiaoqing4; Hu, Can4; Du, Yian3; Ding, Guangyu3; Chen, Jiahui3; Zhu, Xiu5; Xu, Zhiyuan2,3; Wei, Qing1,6 |
| 刊名 | TRANSLATIONAL CANCER RESEARCH
 |
| 出版日期 | 2022-07-01 |
| 卷号 | 11 |
| ISSN号 | 2218-676X |
| 关键词 | Gastric cancer HER2-positive conversion therapy |
| DOI | 10.21037/tcr-21-2886 |
| 通讯作者 | Xu, Zhiyuan(getfar@foxmail.com) ; Wei, Qing(weiqingmd@163.com) |
| 英文摘要 | Background: Conversion surgery is a treatment that aims for R0 resection of primary advanced gastric cancers (GCs) that have responded well to systemic chemotherapy. We investigated the role of conversion therapy in initially unresectable metastatic cancer with positive HER2 status that responded to chemotherapy plus trastuzumab. Methods: A total of 32 metastatic GC patients who underwent systemic chemotherapy plus trastuzumab sequenced by conversion surgery at Zhejiang Cancer Hospital between 2015 and 2020 were retrospectively reviewed. Results: The observed overall survival (OS) and progression-free survival (PFS) for all the patients were 30.2 and 25.1 months, respectively. The 1-year survival rate was 81.25%, and the 1-year PFS rate was 78.13%. Univariate and multivariate analyses demonstrated that liver metastasis (P=0.021), peritoneal metastasis (P=0.047), para-aortic lymph node metastasis (16a1/b2) (P=0.048), macroscopic type 4 (P=0.027), number of noncurative factors (P=0.011), Yoshida et al. category (P=0.021), and inductive chemotherapy cycles (P=0.025) were independent prognostic factors for OS. Conclusions: HER2-positive patients with potentially resectable disease had a remarkably good prognosis after conversion gastrectomy following trastuzumab treatment. Adequate selection of metastatic GC patients for conversion surgery is recommended. |
| WOS关键词 | NIVOLUMAB PLUS CHEMOTHERAPY ; GASTROESOPHAGEAL JUNCTION ; OPEN-LABEL ; PHASE-II ; OXALIPLATIN ; SURGERY |
| 资助项目 | Medical Health Science and Technology Project of Zhejiang Provincial Health Commission[2022KY684] |
| WOS研究方向 | Oncology |
| 语种 | 英语 |
| 出版者 | AME PUBLISHING COMPANY |
| WOS记录号 | WOS:000811139700001 |
| 资助机构 | Medical Health Science and Technology Project of Zhejiang Provincial Health Commission |
| 源URL | [http://ir.hfcas.ac.cn:8080/handle/334002/130385]  |
| 专题 | 中国科学院合肥物质科学研究院 |
| 通讯作者 | Xu, Zhiyuan; Wei, Qing |
| 作者单位 | 1.Univ Chinese Acad Sci, Chinese Acad Sci, Inst Basic Med & Canc IBMC, Canc Hosp, 1 East Banshan Rd, Hangzhou 310000, Peoples R China 2.Univ Chinese Acad Sci, Chinese Acad Sci, Inst Basic Med & Canc IBMC, Canc Hosp, 1 East Banshan Rd, Hangzhou 310000, Peoples R China 3.Chinese Acad Sci, Univ Chinese Acad Sci Zhejiang Canc Hosp, Inst Basic Med & Canc IBMC, Canc Hosp, Hangzhou, Peoples R China 4.Second Clin Med Coll Zhejiang Chinese Med Univ, Hangzhou, Peoples R China 5.Chinese Acad Sci, Univ Chinese Acad Sci Zhejiang Canc Hosp, Inst Basic Med & Canc IBMC, Canc Hosp, Hangzhou, Peoples R China 6.Chinese Acad Sci, Univ Chinese Acad Sci Zhejiang Canc Hosp, Inst Basic Med & Canc IBMC, Canc Hosp, Hangzhou, Peoples R China |
| 推荐引用方式 GB/T 7714 | Zhang, Yanqiang,Xu, Xiaoqing,Hu, Can,et al. Trastuzumab in combination with chemotherapy for HER2-positive metastatic gastric cancer patients underwent conversion therapy[J]. TRANSLATIONAL CANCER RESEARCH,2022,11. |
| APA | Zhang, Yanqiang.,Xu, Xiaoqing.,Hu, Can.,Du, Yian.,Ding, Guangyu.,...&Wei, Qing.(2022).Trastuzumab in combination with chemotherapy for HER2-positive metastatic gastric cancer patients underwent conversion therapy.TRANSLATIONAL CANCER RESEARCH,11. |
| MLA | Zhang, Yanqiang,et al."Trastuzumab in combination with chemotherapy for HER2-positive metastatic gastric cancer patients underwent conversion therapy".TRANSLATIONAL CANCER RESEARCH 11(2022). |
入库方式： OAI收割
来源：合肥物质科学研究院
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。